Pure Red Cell Aplasia Induced by Erythropoiesis-Stimulating Agents
Open Access
- 1 January 2008
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Clinical Journal of the American Society of Nephrology
- Vol. 3 (1), 193-199
- https://doi.org/10.2215/cjn.02440607
Abstract
Pure red cell aplasia in patients who are treated for anemia of chronic kidney disease with erythropoiesis-stimulating agents such as epoetin was first reported in 1998. Although the incidence of pure red cell aplasia peaked in 2002, it remains important for nephrologists to know how to investigate a suspected case of pure red cell aplasia and how to identify other causes of hyporesponsiveness to erythropoiesis-stimulating agents, which account for the vast majority of such cases. The authors reviewed the current status of information in the literature and drew on their personal experiences with patients regarding the diagnosis and management of epoetin-induced pure red cell aplasia. The mechanism for development of epoetin-induced pure red cell aplasia remains unconfirmed. It generally occurs after the production of neutralizing anti-erythropoietin antibodies. Elucidation of a suspected pure red cell aplasia case requires a systematic approach, beginning with simple measurements such as blood cell counts, because most cases of erythropoiesis-stimulating agent hyporesponsiveness are attributable to other causes. If these criteria indicate that the patient's response to erythropoiesis-stimulating agent therapy is very poor, then bone marrow examination and measurement of anti-erythropoietin antibodies is justified. If pure red cell aplasia is confirmed, then cessation of erythropoiesis-stimulating agent therapy and initiation of immunosuppressive therapy are recommended. Continued study of epoetin-induced pure red cell aplasia is needed to help nephrologists prevent or manage future cases and will have implications for the use of other protein-based therapeutic agents.This publication has 32 references indexed in Scilit:
- Biophysical Comparability of the Same Protein From Different Manufacturers: A Case Study Using Epoetin Alfa From Epogen® and Eprex®Journal of Pharmaceutical Sciences, 2006
- Effects of protein aggregates: An immunologic perspectiveThe AAPS Journal, 2006
- CPR 3.5. Evaluating and Correcting Persistent Failure to Reach or Maintain Intended HbAmerican Journal of Kidney Diseases, 2006
- Current Methods for Detecting Antibodies against Erythropoietin and Other Recombinant ProteinsClinical and Vaccine Immunology, 2005
- Successful resumption of epoetin alfa after rituximab treatment in a patient with pure red cell aplasiaAmerican Journal of Kidney Diseases, 2004
- Pure Red-Cell Aplasia and Epoetin TherapyThe New England Journal of Medicine, 2004
- Treatment of erythropoietin-induced pure red cell aplasia: a retrospective studyThe Lancet, 2004
- Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant ErythropoietinThe New England Journal of Medicine, 2002
- In vitro bioassay for human erythropoietin based on proliferative stimulation of an erythroid cell line and analysis of carbohydrate-dependent microheterogeneityJournal of Pharmaceutical and Biomedical Analysis, 1996
- Acquired pure red cell aplasiaAmerican Journal of Hematology, 1987